Gout Clinical Trial
— DEteCTOfficial title:
Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration
NCT number | NCT03038386 |
Other study ID # | NL54454.100.15 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | June 2019 |
Rationale: Gout is a disease with growing incidence and complexity due to increased life
expectancy, co-morbidity and medication. The disease can be diagnosed by microscopy,
demonstrating monosodium uric acid (MSU) in synovial fluid of the affected joint or in tophi
(subcutaneous or peritendinous MSU depositions). In daily practice, however, the diagnosis is
difficult to ascertain due to sampling error (no synovial fluid acquired because the needle
was not exactly placed in the affected joint, or the location of the gout might have been
extra-articular e.g. around tendons) or to a different cause of acute arthritis (e.g.
infection, reactive arthritis). Recently, Dual Energy CT scan has become available. This
technique allows the visualization and quantification of MSU. Although imaging modalities
such as DECT show promise in the classification of gout, the studies to date have been small
and have primarily involved people with established disease.
A study with cross-sectional design in which patients for whom the clinical questions "does
this patient have gout?" are referred for participation may contribute to assess the value of
DECT scan in diagnosing acute arthritis caused by gout.
Objective: Assessment of value of DECT scan in diagnosing acute arthritis, caused by gout.
Study design: Prospective Study population: Patients with acute mono or oligo arthritis
without prior diagnosis, the rheumatologist has an indication for diagnostic needle
aspiration.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: In current daily practice, patients with acute mono- or oligo-arthritis without
prior diagnosis undergo a diagnostic aspiration of the affected joint. This can be done by
blind aspiration or ultra sound guided aspiration depending on the judgement of the
rheumatologist. The aspirated synovial fluid is then assessed by polarized microscopy to
detect MSU crystals. The diagnostic value of DECT in acute gout attacks had not yet been
established and is therefore not used in daily practice. In this study all patients undergo
DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If
the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained
prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound
guided aspiration will take place, with knowledge of DECT results, followed by repeat
microscopy
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age > 18 years - Mono or oligo arthritis (2-3 swollen joints) - Indication for diagnostic aspiration of an inflamed joint in which gout is one of the possibilities Exclusion Criteria: - Polyarthritis ( up to 4 swollen joint); - Chrystal proven gout in history - Patient is on uric acid lowering therapy (Allopurinol, Benzbromaron, Febuxostat) - Hip arthritis* - Metal or prosthesis of the inflamed joint - Highly suspicion of infectious arthritis - Pregnancy - Contra indication of joint aspiration (skin infection, hemophilia) - No informed consent |
Country | Name | City | State |
---|---|---|---|
Netherlands | Meander Medical Center | Amersfoort | Utrecht |
Lead Sponsor | Collaborator |
---|---|
Meander Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The sensitivity and specificity (95% CI) of DECT scanning for the detection of MSU deposits | 2 weeks | ||
Secondary | clinical and laboratory predicators of positive DECT scan in patients with acute mono or oligo arthritis | 2 weeks | ||
Secondary | number of participants, in whom the first aspirate demonstrated no MSU and/or no synovial fluid, with MSU demonstrated after ultrasound guided joint aspiration | 2 weeks | ||
Secondary | number of participants with positive DECT lesions, in whom the first aspirate(s) demonstrated no MSU and/or no synovial fluid with MSU demonstrated after ultrasound guided joint aspiration at the place of positive DECT lesion | 2 weeks | ||
Secondary | cost of the gout diagnostic strategies (blind joint aspiration, ultrasound guided joint aspiration, DECT) will be calculated | 2 weeks | ||
Secondary | Patient satisfaction: What does the patient experience as the most patient-friendly way of diagnosing gout: DECT scan, ultrasound-guided joint aspiration or blind aspiration? | VAS DECT, blind joint aspiration, ultrasound guided joint aspiration | 2 weeks | |
Secondary | correlation between cardiovascular risk and the urate volume on DECT | correlation coefficient between cardiovascular risk (SCORE European and ACC/AHA) and the urate volume on DECT | 2 weeks | |
Secondary | number of patients with clinical diagnosis gout 6 and 12 month after het DECT | 6 and 12 month | ||
Secondary | number of patients on urate lowering medication 6 and 12 month after the DECT | 6 and 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04060173 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
|
Phase 1 | |
Not yet recruiting |
NCT06187519 -
UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
|
N/A | |
Completed |
NCT03635957 -
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
|
Phase 4 | |
Completed |
NCT04966325 -
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
|
Early Phase 1 | |
Completed |
NCT03015948 -
A Single Dose Study of SHR4640 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT02855437 -
Novel Methods for Ascertainment of Gout Flares -A Pilot Study
|
N/A | |
Active, not recruiting |
NCT02702375 -
Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases
|
N/A | |
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT00985127 -
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
|
Phase 2 | |
Completed |
NCT00995618 -
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
|
Phase 2 | |
Terminated |
NCT04987294 -
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT03291782 -
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT03388515 -
A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT06189404 -
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
|
Phase 1 | |
Enrolling by invitation |
NCT03336203 -
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
|
Phase 4 | |
Recruiting |
NCT05586958 -
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
|
Phase 3 | |
Recruiting |
NCT04047394 -
A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05507723 -
Tight Control of Gouty Arthritis Compared to Usual Care
|
N/A | |
Recruiting |
NCT06056570 -
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
|
Phase 1/Phase 2 | |
Completed |
NCT02557126 -
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
|
Phase 2 |